effect of a newly synthesised sulfonylurea derivative 1- [P- [3,5 dimethyl-pyrazole -1] carbomoylbenzene sulfonyl] - 3-cyclohexylurea [cycle SCC] on plasma lipids, some electrolytes and liver function tests in the rabbit

ABSTRACT

The effects of the acute and prolonged administration of a newly synthesised sulfonylurea derivative, [Cycle SCC], on plasma free fatty acids [FFA], triglycerides and cholesterol levels were studied. Serum sodium and potassium levels, in addition to some liver function tests were also measured. Results revealed a significant decrease in plasma FFA, of both normal and alloxan diabetic rabbits, when measured after the administration of one single dose of the drug. Moreover, after the prolonged administration of Cycle SCC, plasma FFA, triglycerides and cholesterol levels were significantly decreased. A significant decrease in serum sodium and potassium levels of diabetic, but not of healthy, rabbits was evident. No significant change was observed in the studied liver function tests [viz, serum glutamic pyruvic transaminase [SGPT, serum glutamic oxalacetic transaminase [SGOT] and serum alkaline phosphatase], indicating the relative safety of Cycle SCC from hepatotoxic effects